Table 1.
Total N = 136 |
Candidemia due to C. albicans N = 78 |
Candidemia due to non-albicans Candida species N = 58 |
P value | |
---|---|---|---|---|
Age (years) | 62.1 ± 14.9 | 61.0 ± 17.2 | 63.5 ± 11.1 | 0.32 |
Male gender | 84 (61.8) | 45 (57.7) | 39 (67.2) | 0.26 |
SAPS II | 53.8 ± 20.4 | 57.4 ± 22.8 | 48.7 ± 15.5 | 0.015 |
SOFA | 9.6 ± 4.7 | 10.4 ± 4.7 | 8.6 ± 4.6 | 0.03 |
Underlying disease* | 0.35 | |||
Absent or nonfatal | 63 (46.3) | 37 (47.4) | 26 (44.8) | |
Ultimately fatal | 58 (42.7) | 35 (44.9) | 23 (39.7) | |
Rapidly fatal | 15 (11.0) | 6 (7.7) | 9 (15.5) | |
Chronic renal failure | 26 (19.1) | 16 (20.5) | 10 (17.2) | 0.63 |
Type 1 diabetes mellitus | 16 (11.8) | 8 (10.3) | 8 (13.8) | 0.52 |
Solid neoplastic tumor | 32 (23.5) | 19 (24.4) | 13 (22.4) | 0.79 |
Hematological malignancy | 7 (5.1) | 4 (5.1) | 3 (5.2) | 0.99 |
Immunosuppression | 28 (20.6) | 15 (19.2) | 13 (22.4) | 0.65 |
Corticotherapy | 10 (7.4) | 3 (3.8) | 7 (12.1) | 0.06 |
HIV infection | 2 (1.5) | 2 (2.6) | 0 | 0.17 |
Cancer chemotherapy | 10 (7.4) | 5 (6.4) | 5 (8.6) | 0.78 |
Organ transplantation | 5 (3.7) | 2 (2.6) | 3 (5.2) | 0.50 |
Immunosuppressant therapy | 4 (2.9) | 2 (2.6) | 2 (3.4) | 0.88 |
Intravenous drug use | 2 (1.5) | 1 (1.3) | 1 (1.7) | 0.83 |
Neutropenia (<500/mm3) | 9 (6.6) | 2 (2.6) | 7 (12.1) | 0.04 |
Results are expressed as mean ± SD values or numbers (%) of patients.
HIV: human immunodeficiency virus; SAPS: simplified acute physiology score; SOFA: sepsis-related organ failure assessment
*Classified according to the criteria proposed by McCabe and Jackson [17]